Document Detail


Effect of gonadotropin-releasing hormone agonist and medroxyprogesterone acetate on calcium metabolism: a prospective, randomized, double-blind, placebo-controlled, crossover trial.
MedLine Citation:
PMID:  14607578     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The purpose of this study was to prospectively compare the effectiveness of administering medroxyprogesterone acetate (MPA; 20 mg/d) in either the first (protocol A) or last (protocol B) 12-week period as well as a 6-month course of the GnRH agonist (GnRH-a; leuprolide acetate; 1 mg/d, SC) on calcium (Ca) metabolism. DESIGN: Prospective, randomized, double-blind, placebo-controlled, crossover trial. SETTING: Clinical research center, university hospital. PATIENT(S): Twenty women were randomized into protocol A or B, received either MPA or placebo along with GnRH-a, and were then crossed over at 12 weeks to placebo or MPA, for the final 12-week interval of GnRH-a therapy. INTERVENTION(S): Collection of serum and urine samples and measurement of bone density. Sex hormone, calcitropic hormone, and bone density studies were performed at baseline and at 12 and 24 weeks. RESULT(S): In both protocol A and B, LH and E(2) levels declined by 79%-81% and 83%-90% of the baseline, respectively, at 12 and 24 weeks. Serum Ca, phosphorus, alkaline phosphatase, and osteocalcin; 2-h fasting and 24-h urinary Ca excretion; and urinary hydroxyproline levels all increased significantly during GnRH-a treatment alone. Estimated Ca balance decreased significantly during GnRH-a treatment alone. The addition of MPA attenuated the increases in phosphorus, alkaline phosphatase, osteocalcin, and 2-h fasting and 24-h urinary Ca excretion, and the decrease in estimated Ca balance. Comparison of phase order demonstrated that MPA prevented 24-h urinary Ca excretion and urinary hydroxyproline loss and decline in estimated Ca balance when it was added back during the second 12 weeks (protocol B) but not during the first 12 weeks (protocol A). CONCLUSION (S): We conclude that sequential MPA appears to reverse in part the negative effects of GnRH-a on calcitropic hormones and estimated Ca balance.
Authors:
Bruce R Carr; Neil A Breslau; Noel Peng; Beverley Adams-Huet; Karen D Bradshaw; Michael P Steinkampf
Related Documents :
17604578 - Direct kisspeptin-10 stimulation on luteinizing hormone secretion from bovine and porci...
8399858 - Hypothalamic and posterior pituitary content of vasoactive intestinal peptide and gonad...
1972548 - Hypogonadism in untreated male normoprolactinaemic acromegalics.
2820238 - Evidence for camp as a mediator of gonadotropin secretion from male pituitaries.
10070348 - Control of luteolysis in the one-humped camel (camelus dromedarius).
18823528 - A multivariate analysis of serum nutrient levels and lung function.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Fertility and sterility     Volume:  80     ISSN:  0015-0282     ISO Abbreviation:  Fertil. Steril.     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-11-10     Completed Date:  2003-12-19     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0372772     Medline TA:  Fertil Steril     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1216-23     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9032, USA. bruce.carr@utsouthwestern.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Bone Density
Calcium / blood,  metabolism*,  urine
Cross-Over Studies
Double-Blind Method
Endometriosis / drug therapy,  metabolism*
Female
Gonadotropin-Releasing Hormone / agonists*
Homeostasis
Humans
Leiomyomatosis / drug therapy,  metabolism*
Leuprolide / therapeutic use*
Medroxyprogesterone Acetate / therapeutic use*
Placebos
Uterine Neoplasms / drug therapy,  metabolism*
Grant Support
ID/Acronym/Agency:
M01-RR-00633/RR/NCRR NIH HHS; R01 HD-25860/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Placebos; 33515-09-2/Gonadotropin-Releasing Hormone; 53714-56-0/Leuprolide; 71-58-9/Medroxyprogesterone Acetate; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recurrent first trimester pregnancy loss is associated with uterine septum but not with bicornuate u...
Next Document:  Effect of oral contraceptives and intrauterine devices on midcycle myometrial contractions.